A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers.

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Chemistry

Biochemistry

Medicine

Immunology

Internal Medicine

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.3553